Specify a stock or a cryptocurrency in the search bar to get a summary
Longeveron LLC
LGVNLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Address: Life Science & Technology Park, Miami, FL, United States, 33136
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LGVN
Dividend Analytics LGVN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LGVN
Stock Valuation LGVN
Financials LGVN
Results | 2019 | Dynamics |